Survival benefit of tamoxifen in male breast cancer: prospective cohort analysis.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
19
12
2019
accepted:
06
04
2020
revised:
26
03
2020
pubmed:
6
5
2020
medline:
20
2
2021
entrez:
6
5
2020
Statut:
ppublish
Résumé
Due to the lack of prospective data, current treatment of male breast cancer (MBC) is based on information obtained from retrospective analysis or by extrapolation from studies on female patients. In this prospectively enrolled cohort study, we retrospectively examined the survival effect of tamoxifen in MBC patients. In this prospectively enrolled cohort study, 448 patients with MBC were treated between May 2009 and June 2018. The primary endpoint was disease-free survival (DFS). Between May 2009 and June 2018, 448 men with breast cancer were identified, with a median age at diagnosis of 69 years (range 27-96 years). The median follow-up was 39 months (range 3-89 months). Most tumours were larger than 20 mm; invasive ductal carcinoma was of no special histological type and with an intermediate grade of differentiation. Almost half of the men were diagnosed with positive axillary lymph nodes (43.5%). Hormone receptor (HR) positivity was observed in 98.4% of the patients. Notably, DFS among men who did not receive tamoxifen was significantly reduced as compared with those who underwent tamoxifen therapy (P = 0.002). The recurrence rate and mortality in the group of patients without and with tamoxifen treatment were 18.2% and 11.2%, respectively. The most common localisation of metastases was the bone. After adjustment for prognostic factors, we found that tamoxifen was found to reduce the recurrence rate by 68% (hazard ratio HR = 0.32; 95% confidence interval, CI: 0.14-0.74). Tamoxifen treatment was associated with improved DFS for MBC patients. DRKS00009536.
Sections du résumé
BACKGROUND
Due to the lack of prospective data, current treatment of male breast cancer (MBC) is based on information obtained from retrospective analysis or by extrapolation from studies on female patients. In this prospectively enrolled cohort study, we retrospectively examined the survival effect of tamoxifen in MBC patients.
METHODS
In this prospectively enrolled cohort study, 448 patients with MBC were treated between May 2009 and June 2018. The primary endpoint was disease-free survival (DFS).
RESULTS
Between May 2009 and June 2018, 448 men with breast cancer were identified, with a median age at diagnosis of 69 years (range 27-96 years). The median follow-up was 39 months (range 3-89 months). Most tumours were larger than 20 mm; invasive ductal carcinoma was of no special histological type and with an intermediate grade of differentiation. Almost half of the men were diagnosed with positive axillary lymph nodes (43.5%). Hormone receptor (HR) positivity was observed in 98.4% of the patients. Notably, DFS among men who did not receive tamoxifen was significantly reduced as compared with those who underwent tamoxifen therapy (P = 0.002). The recurrence rate and mortality in the group of patients without and with tamoxifen treatment were 18.2% and 11.2%, respectively. The most common localisation of metastases was the bone. After adjustment for prognostic factors, we found that tamoxifen was found to reduce the recurrence rate by 68% (hazard ratio HR = 0.32; 95% confidence interval, CI: 0.14-0.74).
CONCLUSIONS
Tamoxifen treatment was associated with improved DFS for MBC patients.
CLINICAL TRIAL REGISTRATION
DRKS00009536.
Identifiants
pubmed: 32367072
doi: 10.1038/s41416-020-0857-z
pii: 10.1038/s41416-020-0857-z
pmc: PMC7341811
doi:
Substances chimiques
Antineoplastic Agents, Hormonal
0
Aromatase Inhibitors
0
Tamoxifen
094ZI81Y45
Banques de données
DRKS
['DRKS00009536']
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
33-37Références
Losurdo, A., Rota, S., Gullo, G., Masci, G., Torrisi, R., Bottai, G. et al. Controversies in clinicopathological characteristics and treatment strategies of male breast cancer: a review of the literature. Crit. Rev. Oncol. Hematol. 113, 283–291 (2017).
doi: 10.1016/j.critrevonc.2017.03.013
Leon-Ferre, R. A., Giridhar, K. V., Hieken, T. J., Mutter, R. W., Couch, F. J., Jimenez, R. E. et al. A contemporary review of male breast cancer: current evidence and unanswered questions. Cancer Metastasis 37, 599–614 (2018).
doi: 10.1007/s10555-018-9761-x
Eggemann, H., Ignatov, A., Smith, B. J., Altmann, U., von Minckwitz, G., Rohl, F. W. et al. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res. Treat. 137, 465–470 (2013).
doi: 10.1007/s10549-012-2355-3
Streng, M., Ignatov, A., Reinisch, M., Costa, S. D. & Eggemann, H. A comparison of tumour size measurements with palpation, ultrasound and mammography in male breast cancer: first results of the prospective register study. J. Cancer Res. Clin. Oncol. 144, 381–387 (2018).
doi: 10.1007/s00432-017-2554-8
Eggemann, H., Altmann, U., Costa, S. D. & Ignatov, A. Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer. J. Cancer Res. Clin. Oncol. 144, 337–341 (2017).
doi: 10.1007/s00432-017-2539-7
Eggemann, H., Bernreiter, A. L., Reinisch, M., Loibl, S., Taran, F. A., Costa, S. D. et al. Tamoxifen treatment for male breast cancer and risk of thromboembolism: prospective cohort analysis. Br. J. Cancer 120, 301–305 (2019).
doi: 10.1038/s41416-018-0369-2
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gotzsche, P. C., Vandenbroucke, J. P. et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370, 1453–1457 (2007).
doi: 10.1016/S0140-6736(07)61602-X
Goss, P. E., Reid, C., Pintilie, M., Lim, R. & Miller, N. Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955-1996. Cancer 85, 629–639 (1999).
doi: 10.1002/(SICI)1097-0142(19990201)85:3<629::AID-CNCR13>3.0.CO;2-V
Ribeiro, G. & Swindell, R. Adjuvant tamoxifen for male breast cancer (MBC). Br. J. Cancer 65, 252–254 (1992).
doi: 10.1038/bjc.1992.50
Volm, M. D. Male breast cancer. Curr. Treat. Options Oncol. 4, 159–164 (2003).
doi: 10.1007/s11864-003-0017-8
Roselli, C. E. & Resko, J. A. Sex differences in androgen-regulated expression of cytochrome P450 aromatase in the rat brain. J. Steroid Biochem. Mol. Biol. 61, 365–374 (1997).
doi: 10.1016/S0960-0760(97)80034-9
Shetty, G., Krishnamurthy, H., Krishnamurthy, H. N., Bhatnagar, A. S. & Moudgal, N. R. Effect of long-term treatment with aromatase inhibitor on testicular function of adult male bonnet monkeys (M. radiata). Steroids 63, 414–420 (1998).
doi: 10.1016/S0039-128X(98)00042-7
Anderson, W. F., Althuis, M. D., Brinton, L. A. & Devesa, S. S. Is male breast cancer similar or different than female breast cancer? Breast Cancer Res. Treat. 83, 77–86 (2004).
doi: 10.1023/B:BREA.0000010701.08825.2d
Henriques Abreu, M., Henriques Abreu, P., Afonso, N., Pereira, D., Henrique, R. & Lopes, C. Patterns of recurrence and treatment in male breast cancer: a clue to prognosis? Int. J. Cancer 139, 1715–1720 (2016).
doi: 10.1002/ijc.30225
Ignatov, A., Eggemann, H., Burger, E. & Ignatov, T. Patterns of breast cancer relapse in accordance to biological subtype. J. Cancer Res. Clin. Oncol. 144, 1347–1355 (2018).
doi: 10.1007/s00432-018-2644-2
Ottini, L., Capalbo, C., Rizzolo, P., Silvestri, V., Bronte, G., Rizzo, S. et al. HER2-positive male breast cancer: an update. Breast Cancer 2, 45–58 (2010).
pubmed: 24367166